Amplia to Raise up to $13m for ACCENT and US Trials
Filed with ASX · · 7 pages · English
Summary by 6ix AI
The company aims to raise up to a specified amount through a combination of an entitlement offer, an institutional placement, and a director placement. The funds will be used for trial costs and general working capital, with new shares priced at a specific amount each. The capital raise is expected to issue a significant number of new shares, representing a notable percentage of the company's current shares on issue.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Amplia Therapeutics Ltd. on 6ix
In the deck
Story so far
Earlier from Amplia Therapeutics
- Interim Data From Accent Pancreatic Cancer Trial
- Sixth Confirmed Response in Pancreatic Cancer Trial
- FDA Fast Track Designation for Narmafotinib
- Fifth Confirmed Response in ACCENT Trial
- Amplia Receives R&D Tax Rebate Totalling $3.2 Million
Later from Amplia Therapeutics
- Capital Raise Presentation
- Amplia Successfully Completes Institutional Offer
- Security Class Suspension from Quotation
- App 4D and Financial Report Half Year ended 30 Sep 2024
- Security Class Reinstatement to Quotation - ATXOA
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics